Abstract P6-07-32: Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2 positive subtype is associated with the most favorable outcome

Autor: Vcg Tjan-Heijnen, Dja Lobbezoo, George F. Borm, Adri C. Voogd, F.P.J. Peters, Najb Peters, A.J. van de Wouw, M.W. Dercksen, F.W.P.J. van den Berkmortel, Rjw van Kampen, Tineke J. Smilde, Jmgh van Riel

Publikováno v: Cancer Research. 72:P6-07

Background: In early breast cancer the different subtypes and their prognostic relevance are well known, contrary to the knowledge on prognostic relevance of subtypes in metastatic breast cancer. This study presents survival estimates after diagnosis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::87cfafe6dbe0145cc756e321d2815fc9
https://doi.org/10.1158/0008-5472.sabcs12-p6-07-32

Trastuzumab Resistance in Patients With HER2-Positive Advanced Breast Cancer: Results From the SONABRE Registry.

Autor: Ibragimova KIE; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Geurts SME; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Laczkó D; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands., Meegdes M; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Erdkamp F; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, The Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, The Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, The Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina hospital, Eindhoven, The Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius hospital, Roermond, The Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, The Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek hospital, Helmond, The Netherlands., Peters NAJB; Department of Internal Medicine, St. Jans Gasthuis, Weert, The Netherlands., van de Winkel LMH; Department of Internal Medicine, St Anna Hospital, Geldrop, The Netherlands., van de Wouw AJ; Department of Internal Medicine, Viecuri Medical Centre, Venlo, The Netherlands., de Fallois A; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands., van Kats MACE; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, Maastricht University Medical Center, Maastricht, The Netherlands; GROW-School for Oncology and Reproduction, Maastricht University, Maastricht, The Netherlands. Electronic address: vcg.tjan.heijnen@mumc.nl.

Publikováno v: Clinical breast cancer [Clin Breast Cancer] 2024 Feb; Vol. 24 (2), pp. 103-111. Date of Electronic Publication: 2023 Nov 02.

Outcomes for the first four lines of therapy in patients with HER2-positive advanced breast cancer: results from the SONABRE registry.

Autor: Ibragimova KIE; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Geurts SME; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Meegdes M; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Erdkamp F; Department of Internal Medicine, Zuyderland Medical Center, Sittard-Geleen, the Netherlands., Heijns JB; Department of Medical Oncology, Amphia, Breda, the Netherlands., Tol J; Department of Medical Oncology, Jeroen Bosch Hospital, Den Bosch, the Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, the Netherlands., Dercksen MW; Department of Medical Oncology, Máxima Medical Center, Eindhoven, the Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, the Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, the Netherlands., van de Winkel L; Department of Internal Medicine, St Anna Hospital, Geldrop, the Netherlands., Peters NAJB; Department of Internal Medicine, Sint Jans Gasthuis Hospital, Weert, the Netherlands., Teeuwen-Dedroog NJA; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Vriens IJH; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands., Tjan-Heijnen VCG; Department of Medical Oncology, GROW, School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, PO BOX 5800, 6202 AZ, Maastricht, the Netherlands. vcg.tjan.heijnen@mumc.nl.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2023 Apr; Vol. 198 (2), pp. 239-251. Date of Electronic Publication: 2023 Jan 12.

Neoadjuvant FOLFOXIRI prior to chemoradiotherapy for high-risk ("ugly") locally advanced rectal cancer: study protocol of a single-arm, multicentre, open-label, phase II trial (MEND-IT).

Autor: van den Berg K; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Schaap DP; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Voogt ELK; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Buffart TE; Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Medical Oncology, Amsterdam University Medical Centres, Amsterdam, the Netherlands., Verheul HMW; Department of Medical Oncology, Radboud University Medical Centre, Nijmegen, the Netherlands., de Groot JWB; Department of Medical Oncology, Isala Oncology Centre, Zwolle, the Netherlands., Verhoef C; Department of Surgical Oncology, Erasmus MC Cancer Institute, Rotterdam, the Netherlands., Melenhorst J; Department of Surgery, Maastricht University Medical Centre, Maastricht, the Netherlands., Roodhart JML; Department of Medical Oncology, University Medical Centre Utrecht, Utrecht, the Netherlands., de Wilt JHW; Department of Surgery, Radboud University Medical Centre, Nijmegen, the Netherlands., van Westreenen HL; Department of Surgery, Isala, Zwolle, the Netherlands., Aalbers AGJ; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands., van 't Veer M; Department of Research and Education, Catharina Hospital, Eindhoven, the Netherlands., Marijnen CAM; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.; Department of Radiation Oncology, Leiden University Medical Center, Leiden, the Netherlands., Vincent J; Department of Medical Oncology, Elkerliek Hospital, Helmond, the Netherlands., Simkens LHJ; Department of Medical Oncology, Maxima Medical Centre, Veldhoven, the Netherlands., Peters NAJB; Department of Medical Oncology, St. Jans Hospital, Weert, the Netherlands., Berbée M; Department of Radiation Oncology (MAASTRO), GROW School for Oncology and Reproduction, Maastricht University Medical Centre+, Maastricht, the Netherlands., Werter IM; Department of Medical Oncology, Rijnstate Hospital, Arnhem, the Netherlands., Snaebjornsson P; Department of Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands., Peulen HMU; Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands., van Lijnschoten IG; Department of Pathology, PAMM Laboratory for Pathology and Medical Microbiology, Eindhoven, the Netherlands., Roef MJ; Department of Nuclear Medicine, Catharina Hospital, Eindhoven, the Netherlands., Nieuwenhuijzen GAP; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Bloemen JG; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands., Willems JMWE; Department of Medical Oncology, Anna Hospital, Geldrop, the Netherlands., Creemers GJM; Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands., Nederend J; Department of Radiology, Catharina Hospital, Eindhoven, the Netherlands., Rutten HJT; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands.; GROW School for Oncology and Reproduction, Maastricht University, Maastricht, the Netherlands., Burger JWA; Department of Surgery, Catharina Hospital, Eindhoven, the Netherlands. pim.burger@catharinaziekenhuis.nl.

Publikováno v: BMC cancer [BMC Cancer] 2022 Sep 06; Vol. 22 (1), pp. 957. Date of Electronic Publication: 2022 Sep 06.

The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.

Autor: Meegdes M; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Ibragimova KIE; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Lobbezoo DJA; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands., Vriens IJH; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Kooreman LFS; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.; Department of Pathology, Maastricht University Medical Centre, Maastricht, The Netherlands., Erdkamp FLG; Department of Internal Medicine, Zuyderland Medical Centre, Sittard-Geleen, The Netherlands., Dercksen MW; Department of Internal Medicine, Máxima Medical Centre, Veldhoven, The Netherlands., Vriens BEPJ; Department of Internal Medicine, Catharina Hospital, Eindhoven, The Netherlands., Aaldering KNA; Department of Internal Medicine, Laurentius Hospital, Roermond, The Netherlands., Pepels MJAE; Department of Internal Medicine, Elkerliek Hospital, Helmond, The Netherlands., van de Winkel LMH; Department of Internal Medicine, St Anna Hospital, Geldrop, The Netherlands., Tol J; Department of Internal Medicine, Jeroen Bosch Ziekenhuis, Den Bosch, The Netherlands., Heijns JB; Department of Internal Medicine, Amphia Hospital, Breda, The Netherlands., van de Wouw AJ; Department of Internal Medicine, Viecuri Medical Centre, Venlo, The Netherlands., Peters NAJB; Department of Internal Medicine, St. Jans Gasthuis, Weert, The Netherlands., Hochstenbach-Waelen A; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands., Smidt ML; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands.; Department of Surgery, Maastricht University Medical Centre, Maastricht, The Netherlands., Geurts SME; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands., Tjan-Heijnen VCG; Department of Internal Medicine, Division of Medical Oncology, Maastricht University Medical Centre, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.; GROW School for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands. vcg.tjan.heijnen@mumc.nl.

Publikováno v: Breast cancer research and treatment [Breast Cancer Res Treat] 2022 Apr; Vol. 192 (2), pp. 331-342. Date of Electronic Publication: 2022 Jan 13.